Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies

ACTIVE NOT RECRUITING

NCT01652092

NA

Sponsor: Masonic Cancer Center, University of Minnesota

Summary

This is a standard of care treatment guideline for allogeneic hematopoetic stem cell transplant (HSCT) in patients with primary immune deficiencies.

Key Details

Gender

All

Age Range

Any - 50 Years

Study Type

INTERVENTIONAL

Enrollment

57

Start Date

2012-09-04

Completion Date

2026-12

Last Updated

2026-01-15

Healthy Volunteers

No

Conditions

SCID Omenn's Syndrome Reticular Dysgenesis Wiskott-Aldrich Syndrome Bare Lymphocyte Syndrome Common Variable Immunodeficiency Chronic Granulomatous Disease CD40 Ligand Deficiency Hyper IgM Syndrome X-linked Lymphoproliferative Disease Hemophagocytic Lymphohistiocytosis Griscelli Syndrome Chediak-Higashi Syndrome Langerhan's Cell Histiocytosis

Interventions

DRUG

Alemtuzumab 0.3 mg

0.3 mg/kg intravenously (IV) on days -12 through -10

DRUG

Cyclophosphamide

cyclophosphamide 50 mg/kg IV on days -9 through -6

DRUG

Busulfan

busulfan 0.8 or 1.1 mg/kg IV on days -5 through -2

BIOLOGICAL

Stem Cell Transplantation

Unrelated donor bone marrow will be collected in the usual manner using established parameters determined by the National Marrow Donor Program. A minimum of 3 x 10\^8 nucleated cells/kg recipient weight will be collected with a goal of ≥ 5 x 10\^8 nucleated cells/kg recipient weight. Umbilical cord blood selection will be per the current University of Minnesota Cord Blood Unit Selection algorithm. One or two units may be used to obtain the minimum cell dose. One of the UCB units selected for transplantation must contain ≥ 3.5 x 10\^7 nucleated cells/kg recipient weight based on cell numbers at time of cryopreservation, and the total combined cell dose of both units must be \> 5.0 x 10\^7 nucleated cells/kg.

DRUG

Fludarabine phosphate 40 mg

40 mg/m\^2 IV on days -5 through -2 (for children \< 6 months and/or \< 10 kg weight dose at 1.33 mg/kg)

DRUG

Melphalan

140 mg/m\^2 IV on day -3

DRUG

Alemtuzumab 0.2 mg

0.2 mg/kg intravenously (IV) on days -14 through -10

DRUG

Busulfan

busulfan 0.8 or 1.1 mg/kg IV on days -9 through -6

DRUG

Fludarabine phosphate 30 mg

fludarabine 30 mg/m\^2 IV on days -8 through -4

DRUG

MESNA

administered as per the standard institutional protocol.

Locations (1)

Masonic Cancer Center, University of Minnesota

Minneapolis, Minnesota, United States

Clinical Research Directory